Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Vumerity

- PMLiVE

Biogen and Happify Health team up to create digital platform for MS patients

There are over 2.3 million people living with MS worldwide, with women being more likely to develop the condition than men

- PMLiVE

Innovative Trials partners with MS Society

UK-based patient recruitment company announces its annual charity partnership in support of multiple sclerosis

Innovative Trials

- PMLiVE

EIT Health and Biogen announce winners of first ‘neurotechprize’

The winners, Five Lives and Neurocast, were among ten finalists working to create tech solutions for Alzheimer’s disease

- PMLiVE

Biogen and Eisai announce FDA submission for early Alzheimer’s treatment

The licence application for the treatment of mild cognitive impairment due to Alzheimer’s disease was made as part of the accelerated approval pathway programme

- PMLiVE

Biogen and MedRhythms sign deal worth over $120m for digital therapeutics for MS patients

The collaboration is focused on improving MS patients’ mobility and walking

- PMLiVE

Biogen retracts EMA application for Alzheimer’s drug Aduhelm

The application was pulled after the CHMP said the data provided was not enough to support a marketing authorisation

Roche Basel Switzerland

Roche shares new positive Ocrevus data for MS patients

The CONSONANCE trial showed treatment with Ocrevus resulted in a majority of patients experiencing no disease progression

Biogen Idec building

Biogen shares peer-reviewed publication of Aduhelm phase 3 data

The trial data was published in The Journal of Prevention of Alzheimer’s Disease

Biogen Idec building

SMC approves Biogen’s Vumerity for patients with multiple sclerosis

The new, at-home oral treatment has been developed for adults in Scotland living with relapsing-remitting multiple sclerosis

- PMLiVE

Pfizer’s Paxlovid receives positive opinion from CHMP

If authorised, the drug would be the first COVID-19 oral treatment recommended in the EU

- PMLiVE

Biogen’s Alzheimer’s treatment Aduhelm limited to clinical trial participants in the US

Biogen and The Alzheimer's Association fear that the approach will unfairly exclude patients from therapies and create further healthcare inequities

- PMLiVE

Biogen pays Ionis $60m for licence to develop ASO for spinal muscular atrophy

The licence is worldwide and exclusive and may include future royalty payments

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links